BioSpace News Archive

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market.

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 12, 2021 to discuss its 2020 operating results.

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com (“Liberty” or the “Company”), a provider of high-quality cannabis, announced its financial results for the third quarter ended November 30, 2020

DW Healthcare Partners V, L.P. (“DWHP”), announced today the expiration and final results of its previously announced cash tender offer (the “Tender Offer”) to purchase all of the outstanding ordinary shares (the “Tender Securities”) of Parnell Pharmaceuticals Holdings Ltd (OTC Pink Open Market: PARNF) (“Parnell”) at a price of U.S.$0.40 per share,

Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the closing of a $9 million follow-on public offering.

NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSXV:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce that it has closed a non-brokered private placement (the “Placement”) in which it raised gross proceeds of $370,050.

Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data from the Phase 3 KEYNOTE-598 study evaluating KEYTRUDA, Merck’s anti-PD-1 therapy

Antibiotic-loaded Bone Cement market is anticipated to gain a steady growth pace in 2021 & beyond.